Unigen Issued New Patent on Novel Ingredient

PhytoLogix Discovery Platform Continues to be Validated by New Science

Lacey, WA – January 10, 2006: Unigen Pharmaceuticals, Inc., a leading research and development company of proprietary, biologically active plant-derived ingredients has received notification of approval of a USA patent for Free-B-Ring Flavonoids derived from Chinese Skullcap in supporting its novel Univestin joint health ingredient. This patent brings to151 the number of US and international patents globally awarded or pending for Unigen.

"Unigen’s PhytoLogix discovery platform has yielded many proprietary bioactive natural products”, said Qi Jia, PhD, lead inventor and Chief Science Officer for Unigen Pharmaceuticals. “The previously issued patent on flavans from Acacia species (Patent Number US 7,108,868 B2) and this recently allowed patent on Free-B-Ring flavonoids demonstrates the capability of Unigen’s science program to discover the novel usage of flavonoids in supporting joint health. These patents add significant value to Unigen’s business partners,” said Dr. Jia.

Univestin is a proprietary blend of two individual ingredients - flavans extracted from Acacia catechu and free-b-ring flavonoids from Scutellaria baicalensis. Earlier patents were issued on the Univestin composition and usage, as well as the flavans extract from Acacia catechu to modulate COX/LOX mediated inflammatory conditions. The newly allowed Free-B-Ring flavonoid USA patent will cover this class of natural products from all potential genus and parts of high plants that include Scutellaria genera for treating osteoarthritis; securing final protection of the individual Univestin components.

"With these two issued patents, the IP protection on our 2005 Nutraward winning ingredient – Univestin - is even stronger”, said CEO Regan Miles. “This is good news to Unigen’s important customers and partners that rely on Univestin as the active ingredient in their revolutionary joint support products. Just as important, it should give significant pause to those who might wish to try to infringe on our Univestin product."

Among the patent’s specifically allowable claims is a “method for treating osteoarthritis…[with] an effective amount of a composition comprising a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids and a pharmaceutically acceptable carrier” through “oral, topical, suppository, intravenous, and intradermic, intragaster, intramusclar, intraperitoneal and intravenous administration”.

About Unigen Pharmaceuticals, Inc.
Unigen Pharmaceuticals, Inc. (www.unigenpharma.com ) is a leading natural products research and development company and proprietary ingredients supplier. The company is dedicated to the discovery of botanically derived therapeutic compounds that address consumer health needs and help improve the quality of human life. Its research and discovery process includes extensive work at both the human cell and gene level. Unigen focuses on identifying and studying the unique ingredients of medicinal botanicals and then formulating proprietary raw materials for use in cosmeceutical, nutraceutical, functional food and pharmaceutical products. Unigen is part of the ECONET global family of health and natural product companies which have operations in the United States, Canada, Korea, Mexico, Russia and China.

Contact: Susan Haeger
VP Corporate Communications
(360) 486.7430
[email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.